Meinntech

Notice

[Young Doctor] Meinntech’s Anyfusion, a new-concept drug infusion pump makes a debut.
CEO Lee Sang-bin is confident that this upgraded cylinder-type product will gain much attention in overseas markets. A local small-size medical device manufacturer received good remarks when it introduced a new-concept drug infusion pump. Lee Sang-bin, CEO of Meinntech (photo), met with a group of reporters in a restaurant in Sadang, Seoul on October 28 and said that the company had developed an infusion pump called ‘Anyfusion’ and explained his plan to aim at overseas markets. He emphasized that Anyfusion was a new-concept product that combined the conventional syringe pump with the infusion type pump and expressed his confidence that this product would bring a new sensation to the drug infusion pump market home and abroad. Drug infusion pumps, designed to automatically inject a constant amount of solution or drug into patients, have been used for chronic patients who need continuous infusion of drugs in various medical settings such as hospital wards, emergency rooms, and operating rooms. They are classified into two types- infusion type (where liquid drug is injected at a certain flow rate by application of pressure on an infusion bag) and syringe type (where solution is injected by a syringe at a constant rate) depending on the injection method. On the other hand, Anyfusion employs a cylinder that integrates the functions of syringe and infusion into one pump. Test results show that the product has a flow accuracy of approximately ±2% and a battery duration time of more than 8 hours which are better than those of imported products. He further emphasized that this product is safe because it fundamentally prevents the possibility of causing patients any side effects associated with malfunctions during infusion. The company is planning to market Anyfusion in the first half of next year as soon as it receives the approval from the Ministry of Food and Drug Safety and is also preparing for exportation to such overseas markets as Europe countries and the USA. He mentioned, “This product has received good remarks from overseas buyers who say this new-concept device is more effective and safer than currently available products” and then said, “We are having discussions with leading companies in the drug infusion pump market in order to make aggressive inroads into overseas markets.” He continued to talk about his ambition, “We’d like to make Anyfusion an example that a Korean medical device brand can make a success story in the work market.” Meinntech has once made a presentation to overseas buyers in Seoul on October 21. According to the Report on Medical Device Market issued by the Korea Health Industry Development Institute last year, the drug infusion pump market amounted to about 2 billion US dollars (in 2011) and expected to grow up to about 2.6 billion dollars in 2018. Currently, as many as 15 companies are producing drug infusion pumps in Korea whose production totaled in about 33.6 billion Korean Won in 2011. Article input time Final edit time Reporter: Park Gi-taek Translated by Hong Pyo Chang from KITA

[Young Doctor] Meinntech’s Anyfusion, a new-concept drug infusion pump makes a debut.

CEO Lee Sang-bin is confident that this upgraded cylinder-type product will gain much attention in overseas markets.

A local small-size medical device manufacturer received good remarks when it introduced a new-concept drug infusion pump.

Lee Sang-bin, CEO of Meinntech (photo), met with a group of reporters in a restaurant in Sadang, Seoul on October 28 and said that the company had developed an infusion pump called ‘Anyfusion’ and explained his plan to aim at overseas markets.

He emphasized that Anyfusion was a new-concept product that combined the conventional syringe pump with the infusion type pump and expressed his confidence that this product would bring a new sensation to the drug infusion pump market home and abroad.

Drug infusion pumps, designed to automatically inject a constant amount of solution or drug into patients, have been used for chronic patients who need continuous infusion of drugs in various medical settings such as hospital wards, emergency rooms, and operating rooms. They are classified into two types- infusion type (where liquid drug is injected at a certain flow rate by application of pressure on an infusion bag) and syringe type (where solution is injected by a syringe at a constant rate) depending on the injection method.

On the other hand, Anyfusion employs a cylinder that integrates the functions of syringe and infusion into one pump. Test results show that the product has a flow accuracy of approximately ±2% and a battery duration time of more than 8 hours which are better than those of imported products.

He further emphasized that this product is safe because it fundamentally prevents the possibility of causing patients any side effects associated with malfunctions during infusion. The company is planning to market Anyfusion in the first half of next year as soon as it receives the approval from the Ministry of Food and Drug Safety and is also preparing for exportation to such overseas markets as Europe countries and the USA. He mentioned, “This product has received good remarks from overseas buyers who say this new-concept device is more effective and safer than currently available products” and then said, “We are having discussions with leading companies in the drug infusion pump market in order to make aggressive inroads into overseas markets.”

He continued to talk about his ambition, “We’d like to make Anyfusion an example that a Korean medical device brand can make a success story in the work market.” Meinntech has once made a presentation to overseas buyers in Seoul on October 21. According to the Report on Medical Device Market issued by the Korea Health Industry Development Institute last year, the drug infusion pump market amounted to about 2 billion US dollars (in 2011) and expected to grow up to about 2.6 billion dollars in 2018. Currently, as many as 15 companies are producing drug infusion pumps in Korea whose production totaled in about 33.6 billion Korean Won in 2011.

Article input time

Final edit time

Reporter: Park Gi-taek

Translated by Hong Pyo Chang from KITA

Next	Designated as an alternative military service providing company.
Prev	Registration of a patent in China